Address
3350 W Bayshore Rd.
Palo Alto, CA 94303
United States of America (the)
Phone
650-549-9103
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
March 15, 2021
| Name | Title | Pay | Year Born |
| Divya Patel | Acting Chief Financial Officer | 100,000 | 1990 |
| Satyajit Mitra | Head of Oncology & Executive Director | 225,000 | 1974 |
| Hoyoung Huh | Executive Chairman | 659,000 | 1969 |
| Moddy Wong | Director of Human Resources | 0 | N/A |
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.